Therefore, we consider these three members of the GPAT/AGPAT gene family (AGPAT5, LCLAT1, and LPCAT1) to be valued prognostic biomarkers and potential therapeutic targets for HCC patients. This evidence concerns the gene LCLAT1 and hepatocellular carcinoma.